Asthma
Conditions
Keywords
Asthma
Brief summary
The purpose of this study is to determine that no significant safety issues will be identified following a single dose of AMG 761 in asthma subjects that would preclude further development of AMG 761.
Interventions
DRUGAMG 761
Single dose of AMG 761 on study day 1.
DRUGPlacebo
Single dose of placebo on study day 1.
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Healthy, with no history or evidence of clinically relevant medical or psychiatric disorders (with the exception of asthma) as determined by the investigator in consultation with the Amgen physician where medically appropriate * Immunizations up to date, with a minimum of tetanus, diphtheria, pertussis (td/Tdap), pneumococcal (polysaccharide), influenza (during flu season) and H1N1 (where and when available) vaccinations, as determined by the principal investigator * Body mass index (BMI) in the range of 18 to 35 kg/m2, inclusive * Is a current non-smoker and has not used any tobacco products within the last 6 months and the cumulative smoking history must be ≤ 10 pack years * Clinically stable with a physician diagnosis of asthma for a minimum of 6 months prior to enrollment, and with no change in asthma treatment for at least 3 months prior to enrollment. As needed beta-agonist use (ie, PRN) should be considered a stable treatment * Documented history of atopy to oak, mite, ragweed, timothy grass, Alternaria mold, kochia pollen, aspergillus, or cottonwood within 18 months or positive atopy skin prick test for these specific allergens during the screening period * Additional inclusion criteria apply
Exclusion criteria
* Past history of serious skin rash requiring hospitalization * Active, or history of (within 12 months of enrollment), acute viral infection of the skin (eg, herpes simplex, herpes zoster, or molluscum contagiosum) * Active or history of psoriasis, or a first degree relative with active or known history of psoriasis * First degree relatives with active or history of systemic lupus erythematosus or type 1 diabetes, rheumatoid arthritis or other active autoimmune disorder, as determined by the principal investigator * History of life-threatening anaphylaxis * Experienced an asthma exacerbation (defined as a disease episode resulting in treatment in an emergency room, hospitalization, or an episode treated with oral corticosteroids in dosage of at least 5 mg/day prednisone or equivalent for ≥ 1 week) during the 6 months prior to enrollment * Additional
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of treatment emergent adverse events per subject including clinically significant changes in vital signs, physical examinations, laboratory safety tests and ECGs. | 16 weeks |
| The number of subjects with anti-AMG 761 antibodies after a single dose of AMG 761. | 16 weeks |
Secondary
| Measure | Time frame |
|---|---|
| The maximum observed concentration, time to maximum concentration and the area under the serum concentration-time curve after a single dose of AMG 761. | 16 weeks |
| The circulating CD4+ CCR4+ T cell count. | 16 weeks |
Countries
United States
Outcome results
None listed